AstraZeneca PLC Terminates Diabetes Partnership With BTG plc; Unlikely Contingent Payment will be Made to Shareholders

Published: May 16, 2011

British pharmaceutical group BTG (BGC.L) said partner AstraZeneca (AZN.L) had terminated the development of a diabetes drug, leaving some ex-shareholders of BTG's recently acquired Biocompatibles out of pocket. As part of BTG's 177 million pounds ($287.7 million) buy of oncology specialist Biocompatibles in January, shareholders were offered a right to a potential 0.56 euros per share instead of 10 pence cash, should Astra decide to exercise its option to enter a licence deal for the type 2 diabetes compound, known as CM-3.

Back to news